Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
數字之外：13位分析師討論輝瑞股票
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer (NYSE:PFE) in the last three months.
在過去三個月裏，13位分析師發佈了關於輝瑞（紐交所:PFE）的分析師評級，提供了從看好到看淡的多樣化觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.77, along with a high estimate of $45.00 and a low estimate of $30.00. Witnessing a positive shift, the current average has risen by 2.58% from the previous average price target of $38.77.
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.77, along with a high estimate of $45.00 and a low estimate of $30.00. Witnessing a positive shift, the current average has risen by 2.58% from the previous average price target of $38.77.
Diving into Analyst Ratings: An In-Depth Exploration
深入探討分析師評級：分析師評級的深度探討
The perception of Pfizer by...
通過最近的...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。